BACKGROUND AND OBJECTIVES: Cytotoxic T-lymphocytes (CTL) have been generated in
vitro against chronic myeloid leukemia (CML)-associated BCR/ABL-specific peptides. We …

The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML).
Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA …

The aim of the current study was to determine whether immunization with synthetic peptides
corresponding to the joining region segment of p210 bcr-abl chimeric protein can elicit …

BACKGROUND AND OBJECTIVES: The fusion oncoprotein bcr-abl that characterizes
chronic myeloid leukemia (CML) is a leukemia-specific antigen, which may be immunogenic …

We have previously reported that chaperonerich cell lysates (CRCL) derived from the BCR-
ABL+ 12B1 leukemia activate dendritic cells (DCs) and stimulate leukemia-specific immune …

Chronic myeloid leukemia (CML) is characterized cytogenetically by at (9; 22) translocation
which generates a hybrid bcr‐abl gene, encoding a p210bcr‐abl fusion protein. The …

The BCR/ABL p210 fusion protein has long been considered an ideal target antigen for the
development of immunotherapeutic strategies in chronic myeloid leukaemia (CML) due to its …

Peptide sequences spanning the BCR–ABL protein junction potentially constitute novel
leukaemia‐specific antigens. 9‐mer b3a2 fusion peptides have been reported to bind with …

For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the
BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these …

Bcr-abl fusion peptide–specific CD4+ T-lymphocyte clones have recently been shown to
augment colony formation by chronic myelogenous leukemia (CML) cells in a bcr-abl type …